ClinicalTrials.gg
CompletedNCT00883558Updated Sep 8, 2014Results posted

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

A Phase 2 interventional study of Insulin Lispro and regular human insulin in Diabetes Mellitus, Type 1, sponsored by Halozyme Therapeutics. Completed at 8 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-09-08.

Sponsored by Halozyme Therapeutics · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
31st of 69
48 · median 38
Started
2009
the only one that year
Phase 2
7 of 69
none open now
Registered
11th of 69
by date
Lead sponsor
4 of 69
Halozyme Therapeutics

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 31st largest by enrollment, is the only one that started in 2009, is one of 7 in phase 2, and was the 11th registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 combined with a non-preserved (NP) formulation of regular human insulin (INSULIN-PH20 NP) will be compared to insulin lispro with respect to absorption and action of insulin.

Read the detailed description

The purpose of this study is to compare the safety and tolerability of INSULIN-PH20 NP versus insulin lispro alone.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • recombinant human hyaluronidase (rHuPH20)
  • Insulin lispro
  • regular human insulin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of age 18 to 65 years, inclusive. Females of must use a standard and effective means of for the duration of the study.
  • Participants with Type 1 diabetes mellitus (T1DM) (per World Health Organization [WHO] criteria) treated with insulin for ≥24 months.
  • Participants who use an insulin infusion pump for basal insulin administration must be on the device for at least 90 days prior to screening.
  • (BMI) 18.0 to 35.0 kilograms per square meter (kg/m\^2), inclusive.
  • Glycosylated (HbA1c) ≤7.5 % based on central laboratory screening results.
  • Fasting C-peptide \<0.6 nanograms per milliliter (ng/mL).
  • Participants should be in good general health based on medical history and physical examination and without medical conditions that might prevent the completion of study drug injections and assessments required in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to any component of any of the study drugs in this study.
  • Previous enrollment in this study. Participants who fail Screening may attempt to rescreen into the study.
  • A participant who has proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.
  • As judged by the Investigator, active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on [ECG]), hepatic, neurological, renal, genitourinary, or hematological systems.
  • As judged by the Investigator, uncontrolled hypertension (diastolic blood pressure ≥100 millimeters of mercury [mmHg] and/or systolic blood pressure ≥160 mmHg after 5 minutes in the supine position). Three attempts may be performed to measure blood pressure.
  • History of any illness or disease that in the opinion of the Investigator might confound the results of the study or pose additional risk in administering the study drugs to the participant.
  • As judged by the Investigator, clinically significant findings in routine laboratory data.
  • Use of drugs (such as systemic ) that may interfere with the interpretation of study results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia.
  • Recurrent severe hypoglycemia (more than 2 episodes over the last 6 months) or hypoglycemic unawareness, as judged by the Investigator.
  • Current addiction to alcohol or substances of abuse, as determined by the Investigator.
  • Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives, or barrier methods).
  • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation in this study.
  • Receipt of any drug within 4 weeks of Screening.
  • Any condition (intrinsic or extrinsic) that in the judgment of the Investigator will interfere with study participation or evaluation of data. Examples would include: renal insufficiency (serum creatinine >1.5 milligrams per deciliter [mg/dL] for males or >1.4 mg/dL for females), congestive heart failure required medication treatment, and cardiac disease with (NYHA) Functional Capacity of III/IV.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    INSULIN-PH20 NP / Insulin Lispro

    All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually. Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle. INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually. Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually. Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump.

    Drug: Insulin Lispro · Drug: regular human insulin · Drug: recombinant human hyaluronidase PH20 · Drug: Insulin glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Postprandial Glucose Excursion

    A 2-hour postprandial glucose excursion was measured for 3 meals over 3 days during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle). For each of the 3 days, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal value as determined by 8-point glucose monitoring. The average of all excursions over the 3 days for the corresponding treatment cycle is presented.

    Time frame: Week 14 and Week 26

Secondary outcomes

  1. Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring

    Participants were provided a continuous glucose monitoring (CGM) device, consisting of a sensor, transmitter, and receiver. Total time the participant's blood glucose was outside the 71-139 mg/dL range during 3 days of CGM during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle) is presented.

    Time frame: Week 14 and Week 26

  2. Number of Participants With Hypoglycemic Events

    The number of participants with at least one hypoglycemic event (HE) reported during the entire study is presented. Additionally, the number of participants with severe HEs (those that necessitated administration of carbohydrate or glucagon, or resuscitation, by another person) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through Week 29

07

Results

Posted Sep 8, 2014

Participant flow

Titration Period (Weeks 0 to 4)
Participant flow — Titration Period (Weeks 0 to 4)
MilestoneAll Enrolled ParticipantsINSULIN-PH20 NP First, Then Insulin LisproInsulin Lispro First, Then INSULIN-PH20 NP
Started4800
Completed4600
Not completed200
Withdrew: Withdrawal by subject200
First Treatment Cycle (Weeks 4 to 16)
Participant flow — First Treatment Cycle (Weeks 4 to 16)
MilestoneAll Enrolled ParticipantsINSULIN-PH20 NP First, Then Insulin LisproInsulin Lispro First, Then INSULIN-PH20 NP
Started02224
Received at least 1 dose of study drug02224
Completed01923
Not completed031
Withdrew: Adverse event010
Withdrew: Withdrawal by subject011
Withdrew: Protocol violation010
Second Treatment Cycle (Weeks 16 to 28)
Participant flow — Second Treatment Cycle (Weeks 16 to 28)
MilestoneAll Enrolled ParticipantsINSULIN-PH20 NP First, Then Insulin LisproInsulin Lispro First, Then INSULIN-PH20 NP
Started01923
Received at least 1 dose of study drug01923
Completed01922
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPostprandial Glucose Excursion

A 2-hour postprandial glucose excursion was measured for 3 meals over 3 days during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle). For each of the 3 days, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal value as determined by 8-point glucose monitoring. The average of all excursions over the 3 days for the corresponding treatment cycle is presented.

Time frame:
Week 14 and Week 26
Reported as:
Mean · milligrams per deciliter (mg/dL)
Postprandial Glucose Excursion
milligrams per deciliter (mg/dL)INSULIN-PH20 NPInsulin Lispro
Postprandial Glucose Excursion17.23 ± 36.04014.47 ± 35.113
Statistical analysis
  • INSULIN-PH20 NP vs Insulin Lispro · Mixed Models Analysis · p = 0.3217 · Ls mean difference: 3.06Adjustments included treatment, phase, and treatment sequence as fixed effects and participant within treatment sequence as a random effect.
SecondaryTime Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring

Participants were provided a continuous glucose monitoring (CGM) device, consisting of a sensor, transmitter, and receiver. Total time the participant's blood glucose was outside the 71-139 mg/dL range during 3 days of CGM during each treatment cycle (3 days during Week 14 of the first treatment cycle and 3 days during Week 26 of the second treatment cycle) is presented.

Time frame:
Week 14 and Week 26
Reported as:
Mean · hours
Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring
hoursINSULIN-PH20 NPInsulin Lispro
Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring14.58 ± 3.15513.37 ± 3.933
SecondaryNumber of Participants With Hypoglycemic Events

The number of participants with at least one hypoglycemic event (HE) reported during the entire study is presented. Additionally, the number of participants with severe HEs (those that necessitated administration of carbohydrate or glucagon, or resuscitation, by another person) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through Week 29
Reported as:
Number · participants
Number of Participants With Hypoglycemic Events
participantsINSULIN-PH20 NPInsulin Lispro
Overall4543
Severe HE20

Adverse events

Collected over An adverse event was considered treatment-emergent if the start date of the event was on or after the date of randomization.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INSULIN-PH20 NP Treatment Period—2/45 (4.4%)17/45 (37.8%)
Insulin Lispro Treatment Period—1/43 (2.3%)11/43 (25.6%)
Most frequent serious events
Most frequent serious events
EventINSULIN-PH20 NP Treatment PeriodInsulin Lispro Treatment Period
Uterine haemorrhageReproductive system and breast disorders1/220/20
HaemothoraxInjury, poisoning and procedural complications0/451/43
Rib fractureInjury, poisoning and procedural complications0/451/43
Intervertebral disc degenerationMusculoskeletal and connective tissue disorders1/450/43
Most frequent other events
Showing 10 of 11
Most frequent other events
EventINSULIN-PH20 NP Treatment PeriodInsulin Lispro Treatment Period
NasopharyngitisInfections and infestations7/457/43
Upper respiratory tract infectionInfections and infestations1/453/43
CoughRespiratory, thoracic and mediastinal disorders3/450/43
Food poisoningGastrointestinal disorders0/452/43
Back painMusculoskeletal and connective tissue disorders0/452/43
SinusitisInfections and infestations2/451/43
BronchitisInfections and infestations2/450/43
Fungal infectionInfections and infestations2/451/43
Injection site haematomaGeneral disorders2/451/43
HypoglycaemiaMetabolism and nutrition disorders2/450/43

Baseline characteristics

Participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)All Randomized Participants
Mean41.6 ± 13.28
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female22
Male24
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Randomized Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White44
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Randomized Participants
Hispanic or Latino2
Not Hispanic or Latino44
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Randomized Participants
United States46
08

Study locations

8 sites
  • Barbara Davis Center for Childhood Diabetes
    Aurora, Colorado 80045, United States
  • Diabetes Research Institute
    Miami, Florida 33136, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • UNC Diabetes Care Center/Highgate Specialty Center
    Durham, North Carolina 27713, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Texas Diabetes and Endocrinology
    Austin, Texas 78731, United States
  • West Olympia Internal Medicine
    Olympia, Washington 98502, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Feb 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2009
First posted
Apr 17, 2009
Start
May 2009
Primary completionActual
Feb 2010
CompletionActual
Apr 2010
Results first posted
Sep 8, 2014
Last update
Sep 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00883558
Responsible party
Sponsor
First posted
Apr 17, 2009
Start date
May 2009
Primary completion
Feb 2010
Completion
Apr 2010
Results posted
Sep 8, 2014
Last update
Sep 8, 2014

Study contacts

Douglas Muchmore, M.D.
study director · Halozyme Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Hyaluronidase (human recombinant)

Start the discussion